0RA9.L - ABIVAX Société Anonyme

LSE - LSE Prezzo differito. Valuta in EUR.

ABIVAX Société Anonyme

7-11 boulevard Haussmann
Paris 75009
France
33 1 53 83 08 41
https://www.abivax.com

Settore/i
Settore
Impiegati a tempo pieno22

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Philippe Pouletty M.D., Ph.D.Founder & DirectorN/DN/D1958
Mr. Marc M. P. de Garidel M.B.A.CEO & Interim Chair of BoardN/DN/D1958
Mr. Didier BlondelEVP, CFO & Board Sec.N/DN/DN/D
Ms. Raquel LizarragaInvestor Relations Mang.N/DN/DN/D
Ms. Regina JehleVP of CommunicationsN/DN/DN/D
Anne PascardHR Mang.N/DN/DN/D
Mr. Pierre Courteille M.B.A.Chief Bus. OfficerN/DN/DN/D
Mr. Sheldon SloanChief Medical OfficerN/DN/DN/D
Mr. Michael Ferguson B.S., M.B.A.Chief Commercial OfficerN/DN/DN/D
Mr. Paul GinesteVP Clinical OperationsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that modulate the body's natural immune system to treat patients with chronic inflammatory, infectious, and cancer diseases. The company's products include obefazimod that is in Phase III clinical trials for the treatment of ulcerative colitis; Phase IIb clinical trials for the treatment of Crohn's Disease; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and in a pre-clinical trial for the treatment of Respiratory Syncytial Virus. It also develops ABX 196, an immune enhancer candidate that is in Phase 2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue, influenza, and respiratory syncytial virus. It has license agreement with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Governance aziendale

L'ISS Governance QualityScore di ABIVAX Société Anonyme al 1 giugno 2023 è 10. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 10; diritti degli azionisti: 7; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.